Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S100A4 | P26447 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 5/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | BLM | P54132 | 4/20 | 0.41 |
| ▸ | THRB | P10828 | 3/20 | 0.41 |
| ▸ | RECQL | P46063 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.41 |
| ▸ | CASP7 | P55210 | 2/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | KMT5A | Q9NQR1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2599344 | 0.68 | S100A4 (1.00) | S100A4MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL8260286 | 0.66 | MEN1 (0.46) | S100A4MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL4658410 | 0.66 | MEN1 (0.42) | S100A4MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL416283 | 0.65 | MALT1 (0.51) | S100A4MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL5940345 | 0.63 | S100A4 (0.53) | S100A4MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL28281313 | 0.63 | IDO1 (0.47) | S100A4MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL4657699 | 0.61 | S100A4 (0.67) | S100A4MEN1KMT2AALDH1A1KDM4E | |
| 9,10-Phenanthrenequinone SCHEMBL43050 | 0.60 | MEN1 (1.00) | S100A4MEN1KMT2AALDH1A1KDM4E | |
| 9,10-Phenanthrenequinone SCHEMBL31598775 | 0.60 | MEN1 (1.00) | S100A4MEN1KMT2AALDH1A1KDM4E | |
| 9,10-Phenanthrenequinone SCHEMBL29384320 | 0.60 | MEN1 (1.00) | S100A4MEN1KMT2AALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1545507-A4 | ACTIVATED CHECKPOINT THERAPY AND METHODS OF USE THEREOF | ARQULE INC (US) | 2009-04-22 | — | — | EP | claimed |
| EP-1545507-A2 | ACTIVATED CHECKPOINT THERAPY AND METHODS OF USE THEREOF | Arqule, Inc. (US) | 2005-06-29 | — | — | EP | claimed |
| US-20040209942-A1 | Activated checkpoint therapy and methods of use thereof | BETH ISRAEL DEACONESS MEDICAL CENTER | 2004-10-21 | — | — | US | claimed |
| WO-2004007531-A2 | ACTIVATED CHECKPOINT THERAPY AND METHODS OF USE THEREOF | ARQULE, INC. (US) | 2004-01-22 | — | — | WO | claimed |
| US-20230255904-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING NAPHTHOQUINONE-BASED COMPOUND AND IMMUNE CHECKPOINT INHIBITOR AS ACTIVE INGREDIENTS | NADIANBIO LTD. (KR) | 2023-08-17 | — | — | US | disclosed |
| US-20230255904-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING NAPHTHOQUINONE-BASED COMPOUND AND IMMUNE CHECKPOINT INHIBITOR AS ACTIVE INGREDIENTS | NADIANBIO LTD. (KR) | 2023-08-17 | — | — | US | disclosed |
| EP-4180034-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING NAPHTHOQUINONE-BASED COMPOUND AND IMMUNE CHECKPOINT INHIBITOR AS ACTIVE INGREDIENTS | NADIANBIO Ltd. (KR) | 2023-05-17 | — | — | EP | disclosed |
| US-20140154319-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF CARDIAC DISEASE | KWAK TAEHWAN (KR) | 2014-06-05 | — | — | US | disclosed |
| US-20140154319-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF CARDIAC DISEASE | KWAK TAEHWAN (KR) | 2014-06-05 | — | — | US | disclosed |
| US-20130302422-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT AND PREVENTION OF KIDNEY DISEASES | KT & G CORPORATION (KR) | 2013-11-14 | — | — | US | disclosed |
| US-20130302422-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT AND PREVENTION OF KIDNEY DISEASES | KT & G CORPORATION (KR) | 2013-11-14 | — | — | US | disclosed |
| US-20120289577-A1 | COMPOSITION FOR TREATING OR PREVENTING HEARING LOSS COMPRISING NAPHTHOQUINONE-BASED COMPOUNDS | KT&G LIFE SCIENCES CORPORATION (KR) | 2012-11-15 | — | — | US | disclosed |
| EP-1545507-A2 | ACTIVATED CHECKPOINT THERAPY AND METHODS OF USE THEREOF | Arqule, Inc. (US) | 2005-06-29 | — | — | EP | disclosed |
| US-20050054018-A1 | Activated checkpoint therapy and methods of use thereof | LI CHIANG J (US) | 2005-03-10 | — | — | US | disclosed |
| US-20040266857-A1 | Novel lapachone compounds and methods of use thereof | HINES GLOBAL EDUCATION | 2004-12-30 | — | — | US | disclosed |
| US-20040253216-A1 | Activated checkpoint therapy and methods of use thereof | LI CHIANG J (US) | 2004-12-16 | — | — | US | disclosed |
| US-20040253730-A1 | Activated checkpoint therapy and methods of use thereof | LI CHIANG J (US) | 2004-12-16 | — | — | US | disclosed |
| US-20040209942-A1 | Activated checkpoint therapy and methods of use thereof | BETH ISRAEL DEACONESS MEDICAL CENTER | 2004-10-21 | — | — | US | disclosed |
| WO-2004045557-A2 | NOVEL LAPACHONE COMPOUNDS AND METHODS OF USE THEREOF | ARQULE, INC. (US) | 2004-06-03 | — | — | WO | disclosed |
| WO-2004007531-A2 | ACTIVATED CHECKPOINT THERAPY AND METHODS OF USE THEREOF | ARQULE, INC. (US) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040253730-A1 | Activated checkpoint therapy and methods of use thereof | TP53, CHEK1, CHEK2 | S100A4 3513/4885MEN1 4413/4885KMT2A 2159/4885 |
| US-20040266857-A1 | Novel lapachone compounds and methods of use thereof | XIAP, MKI67, PIN1 | S100A4 657/4885MEN1 2813/4885KMT2A 3488/4885 |
| US-20130302422-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT AND PREVENTION OF KIDNEY DISEASES | REN, ATP6V1B1, SLC5A1 | S100A4 2402/4885MEN1 1424/4885KMT2A 4276/4885 |
| US-20040209942-A1 | Activated checkpoint therapy and methods of use thereof | TP53, CHEK1, CHEK2 | S100A4 3513/4885MEN1 4413/4885KMT2A 2159/4885 |
| US-20120289577-A1 | COMPOSITION FOR TREATING OR PREVENTING HEARING LOSS COMPRISING NAPHTHOQUINONE-BASED COMPOUNDS | NQO1, MT-ND6, MT-ND5 | S100A4 1704/4885MEN1 373/4885KMT2A 2860/4885 |
| US-20230255904-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING NAPHTHOQUINONE-BASED COMPOUND AND IMMUNE CHECKPOINT INHIBITOR AS ACTIVE INGREDIENTS | PDCD1, CD274, PDCD10 | S100A4 2768/4885MEN1 1409/4885KMT2A 3411/4885 |
| US-20140154319-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF CARDIAC DISEASE | TNNT2, TNNC1, TNNI3 | S100A4 2679/4885MEN1 2796/4885KMT2A 4646/4885 |
| US-20040253216-A1 | Activated checkpoint therapy and methods of use thereof | TP53, CHEK1, CHEK2 | S100A4 3513/4885MEN1 4413/4885KMT2A 2159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.